SCYNEXIS Gestione

Gestione criteri di controllo 2/4

SCYNEXIS Il CEO è David Angulo, nominato in Jan2023, e ha un mandato di 1.83 anni. la retribuzione annua totale è $ 1.21M, composta da 46.5% di stipendio e 53.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.38% delle azioni della società, per un valore di $ 178.50K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.1 anni e 9.5 anni.

Informazioni chiave

David Angulo

Amministratore delegato

US$1.2m

Compenso totale

Percentuale dello stipendio del CEO	46.5%
Mandato del CEO	1.8yrs
Proprietà del CEO	0.4%
Durata media del management	2.1yrs
Durata media del Consiglio di amministrazione	9.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di David Angulo rispetto agli utili di SCYNEXIS?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$36m
Jun 30 2024	n/a	n/a	-US$35m
Mar 31 2024	n/a	n/a	US$101m
Dec 31 2023	US$1m	US$565k	US$67m
Sep 30 2023	n/a	n/a	US$72m
Jun 30 2023	n/a	n/a	US$44m
Mar 31 2023	n/a	n/a	-US$91m
Dec 31 2022	US$1m	US$482k	-US$63m
Sep 30 2022	n/a	n/a	-US$78m
Jun 30 2022	n/a	n/a	-US$49m
Mar 31 2022	n/a	n/a	-US$34m
Dec 31 2021	US$987k	US$461k	-US$33m
Sep 30 2021	n/a	n/a	-US$46m
Jun 30 2021	n/a	n/a	-US$45m
Mar 31 2021	n/a	n/a	-US$53m
Dec 31 2020	US$939k	US$447k	-US$55m
Sep 30 2020	n/a	n/a	-US$27m
Jun 30 2020	n/a	n/a	-US$36m
Mar 31 2020	n/a	n/a	-US$38m
Dec 31 2019	US$1m	US$437k	-US$54m
Sep 30 2019	n/a	n/a	-US$37m
Jun 30 2019	n/a	n/a	-US$29m
Mar 31 2019	n/a	n/a	-US$31m
Dec 31 2018	US$769k	US$424k	-US$12m
Sep 30 2018	n/a	n/a	-US$22m
Jun 30 2018	n/a	n/a	-US$31m
Mar 31 2018	n/a	n/a	-US$24m
Dec 31 2017	US$768k	US$412k	-US$25m

Compensazione vs Mercato: La retribuzione totale di David ($USD 1.21M ) è superiore alla media delle aziende di dimensioni simili nel mercato UK ($USD 353.74K ).

Compensazione vs guadagni: La retribuzione di David è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

David Angulo (59 yo)

1.8yrs

Mandato

US$1,214,710

Compensazione

Dr. David Gonzalez Angulo, M. D., had been the Chief Medical Officer at SCYNEXIS, Inc. since June 1, 2015. He is President, Director and Chief Executive Officer of SCYNEXIS, Inc. from January 1, 2023. Dr....

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
David Angulo	CEO, President & Director	1.8yrs	US$1.21m	0.38% $ 178.5k
Ivor Macleod	Chief Financial Officer	2.1yrs	US$626.90k	0.028% $ 13.0k
Scott Sukenick	Chief Legal Officer & Corporate Secretary	7yrs	US$936.70k	0.21% $ 99.0k
Daniella Gigante	Vice President of Human Resources & Information Technology	no data	Nessun dato	Nessun dato

2.1yrs

Durata media

59yo

Età media

Gestione esperta: Il team dirigenziale di 0L49 è considerato esperto (durata media dell'incarico 2.1 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
David Angulo	CEO, President & Director	1.8yrs	US$1.21m	0.38% $ 178.5k
Armando Anido	Independent Director	5.8yrs	US$98.75k	0.066% $ 31.0k
David Hastings	Independent Director	9.2yrs	US$104.25k	0.061% $ 28.7k
Ann Hanham	Independent Director	15.9yrs	US$105.25k	0.062% $ 29.3k
Guy MacDonald	Independent Chairman of the Board	10yrs	US$128.75k	0.084% $ 39.7k
Steven Gilman	Independent Director	9.8yrs	US$106.25k	0.063% $ 29.8k
David Denning	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Peter Pappas	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Oliver Cornely	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Barbara Alexander	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Mahmoud Ghannoum	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Paul Nyirjesy	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato

9.5yrs

Durata media

65.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 0L49 sono considerati esperti (durata media dell'incarico 9.5 anni).

SCYNEXIS Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

SCYNEXIS, Inc., Annual General Meeting, Jun 19, 2024

Insufficient new directors

Insufficient new directors

SCYNEXIS, Inc. Announces CEO Changes

Insufficient new directors

Insufficient new directors

Recent updates

SCYNEXIS, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

SCYNEXIS, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

SCYNEXIS, Inc. to Report Q3, 2024 Results on Oct 18, 2024

Second quarter 2024 earnings released: US$0.30 loss per share (vs US$2.56 profit in 2Q 2023)

First quarter 2024 earnings released: EPS: US$0.009 (vs US$0.71 loss in 1Q 2023)

New major risk - Revenue and earnings growth

SCYNEXIS, Inc., Annual General Meeting, Jun 19, 2024

SCYNEXIS, Inc. to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases

New major risk - Share price stability

Full year 2023 earnings released: EPS: US$1.40 (vs US$1.47 loss in FY 2022)

Bronstein, Gewirtz & Grossman LLC Announces SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Third quarter 2023 earnings released: US$0.037 loss per share (vs US$0.62 loss in 3Q 2022)

Holzer & Holzer, LLC Announces Class Action Lawsuit Filed against SCYNEXIS, Inc

Holzer & Holzer, LLC Announces Class Action Lawsuit Filed against SCYNEXIS, Inc

SCYNEXIS, Inc. Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology

SCYNEXIS, Inc. Issues A Voluntary Nationwide Recall of BREXAFEMME® (Ibrexafungerp Tablets) Due to Potential for Cross Contamination with A Non-Antibacterial ß-Lactam Drug Substance

Investor sentiment deteriorates as stock falls 33%

Investor sentiment deteriorates as stock falls 16%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: EPS: US$2.56 (vs US$0.31 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.71 loss per share (vs US$0.17 loss in 1Q 2022)

Forecast breakeven date moved forward to 2023

Forecast to breakeven in 2025

Insufficient new directors

Forecast to breakeven in 2025

Scynexis AnnouncesFDA Approval of Second Indication for Brexafemme® (Ibrexafungerp Tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis

Insufficient new directors

SCYNEXIS, Inc. Announces Positive Results from Pooled Analysis of Two Phase 3 Studies (VANISH-303 and VANISH-306) in the Journal of Women’s Health

SCYNEXIS, Inc. to Report Q3, 2022 Results on Nov 09, 2022

SCYNEXIS, Inc. Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022

SCYNEXIS, Inc. Announces CEO Changes

Insufficient new directors

SCYNEXIS, Inc. Presents Positive Interim Data of ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study

Second quarter 2022 earnings released: US$0.31 loss per share (vs US$0.064 profit in 2Q 2021)

SCYNEXIS, Inc. to Report Q2, 2022 Results on Aug 15, 2022

SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting

SCYNEXIS, Inc. Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME

Scynexis Presents Positive Data from Phase 3 Candle Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections Who Failed Fluconazole During the Issvd Xxvi World Congress and International Vulvovaginal Disease Update

Insufficient new directors

Insufficient new directors

Scynexis Announces Initiation of New Phase 3B Study (Vanquish) to Evaluate Oral Ibrexafungerp as A Treatment for Complicated Vulvovaginal Candidiasis (VVC) in Patients Who Failed to Respond to Treatment with Fluconazole

SCYNEXIS, Inc. Announces Submission of Supplemental New Drug Application of BREXAFEMME® (ibrexafungerp tablets) to the U.S. Food and Drug Administration for an Expanded Indication for the Prevention of Recurrent Vaginal Yeast Infections

SCYNEXIS, Inc., Annual General Meeting, Jun 16, 2022

SCYNEXIS, Inc. Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting

SCYNEXIS, Inc. to Report Q1, 2022 Results on May 12, 2022

No longer forecast to breakeven

Insufficient new directors

SCYNEXIS, Inc. has completed a Follow-on Equity Offering in the amount of $44.988333 million.

SCYNEXIS, Inc. Announces Positive Interim Data from its Ongoing Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections

No longer forecast to breakeven

SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections

Insufficient new directors

Forecast to breakeven in 2024

SCYNEXIS Announces Agreement with FDA on Innovative Strategy for Approval of Oral Ibrexafungerp for Treatment of Invasive Candidiasis

Scynexis, Inc. Announces Peer-Reviewed Publication of Results

Scynexis, Inc. Announces U.S. Availability of BREXAFEMME®

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media